India's Aurobindo Pharma leads race to buy generic drugmaker Zentiva for $5.5 billion, Economic Times reports
20/08/2025 07:46
Aug 20 (Reuters) - Indian drugmaker Aurobindo Pharma ARBN.NS is leading the race to acquire Prague-based generic drugmaker Zentiva 1SKF401E.BV from private equity firm Advent International for up to $5.5 billion, the Economic Times reported on Wednesday, citing people aware of the matter. However, Aurobindo Pharma, in a statement to exchanges, said no binding agreements have been signed by the company's board. (Reporting by Kashish Tandon in Bengaluru; Editing by Harikrishnan Nair) ((Kashish.Tandon@thomsonreuters.com; 8800437922;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11